First Time Loading...
N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 13.61 NOK -3.2%
Updated: May 9, 2024
Section:
 

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 39.99 NOK with a low forecast of 28.28 NOK and a high forecast of 73.32 NOK.

NYKD Lowest Forecast
Wall Street Target
28.28 NOK
108% Upside
NYKD Average Forecast
Wall Street Target
39.99 NOK
194% Upside
NYKD Highest Forecast
Wall Street Target
73.32 NOK
439% Upside
Lowest
Price Target
28.28 NOK
108% Upside
Average
Price Target
39.99 NOK
194% Upside
Highest
Price Target
73.32 NOK
439% Upside
Nykode Therapeutics ASA Competitors:
Price Targets
J
7774
Japan Tissue Engineering Co Ltd
98% Upside
BVXP
Bioventix PLC
41% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
27% Upside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
88% Upside
J
7774
Japan Tissue Engineering Co Ltd
98% Upside
BVXP
Bioventix PLC
41% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
27% Upside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
88% Upside
KMDA
Kamada Ltd
113% Upside
KOD
Kodiak Sciences Inc
13% Upside
IPSC
Century Therapeutics Inc
393% Upside
REGN
Regeneron Pharmaceuticals Inc
12% Upside

Revenue
Forecast

Revenue Estimate
Nykode Therapeutics ASA

For the last 6 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 154%. The projected CAGR for the next 3 years is -8%.

154%
Past Growth
-8%
Estimated Growth
Estimates Accuracy
21%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

See Also

Summary
NYKD intrinsic value, competitors valuation, and company profile.
DCF Valuation
NYKD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NYKD stock valuation using valuation multiples.
Wall Street Estimates
NYKD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NYKD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
39.99 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 39.99 NOK with a low forecast of 28.28 NOK and a high forecast of 73.32 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-8%

For the last 6 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 154%. The projected CAGR for the next 3 years is -8%.

ALPHA SPREAD
Join more than 135,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.